Browsing by Subject "Papillary thyroid carcinoma"

Now showing 1 - 5 of 5
  • Thumbnail Image
    Publication
    Open Access
    C6orf15 expression in thyroid tumors: A promising diagnostic biomarker for the classic variant of papillary thyroid carcinoma
    (2026) Pengju Zhang; Jiaxin Chai; Jiandong Wang; Pengfei Huang; Xudong Gu; Aobo Xu; Biología Celular e Histología; Universidad de Murcia, Departamento de Biologia Celular e Histiologia
    Although C6orf15 is highly expressed in certain human cancers, its expression pattern in papillary tumors remains unclear. In this study, we investigated C6orf15 expression in papillary tumors and assessed its potential as a diagnostic biomarker for histopathological evaluation and fine-needle aspiration cytology (FNAC). We collected a total of 87 formalin-fixed and paraffin embedded (FFPE) thyroid tissue specimens that included: 10 cases with Hashimoto's thyroiditis (HT), 11 with follicular adenomas (FAs), two with non-invasive follicular thyroid neoplasms with papillary-like nuclear feature (NIFTP), six with follicular thyroid carcinomas (FTCs), three with invasive encapsulated follicular variant of papillary thyroid carcinomas (IEFVPTCs), three with medullary thyroid carcinomas (MTCs), and 52 with papillary thyroid carcinomas (PTCs). Additionally, 33 FNAC samples from thyroid nodules were analyzed, comprising three samples of FA, five atypia of undetermined significance (AUS), and 25 cases of PTC. Immunohistochemical (IHC) staining was performed to assess C6orf15 expression in thyroid tumor tissues and FNAC samples. We conducted BRAF V600E mutation analysis via Sanger sequencing and IHC and discerned that C6orf15 expression was absent in normal follicular epithelial cells, FA, NIFTP, TFC, and MTC. The positivity rates for C6orf15 in FFPE samples were as follows: 66.7% for IEFVPTC, 86.5% for PTC, and 60.0% for AUS. In FNAC samples, the positivity rate was 80.0% for PTC. A significant positive correlation was observed between C6orf15 expression and the BRAF V600E mutation in PTC tissues (p<0.001), but no such association was found in FNAC samples (p=0.230). C6orf15 exhibited high expression levels in the majority of IEFVPTC (66.7%), PTC tissues (86.5%), and FNAC samples (80.0%). These findings suggest that C6orf15 constitutes a promising diagnostic biomarker for the classic variant of PTC and is applicable to histo pathological assessment and FNAC-based diagnosis.
  • Thumbnail Image
    Publication
    Open Access
    Circular RNA hsa_circ_0003892 promotes the development of papillary thyroid carcinoma by regulating the miR-326/LASP1 axis
    (Universidad de Murcia, Departamento de Biologia Celular e Histiologia, 2023) Han, Peng; Liu, Junsong; Zhao, Qian; Li, Honghui; Zhang, Ting; Li, Baiya; Niu, Xiaorong
    Background. Thyroid cancer is the most common malignancy of the endocrine system. Circular RNA (circRNA) is recognized as a key regulator of tumorigenesis in papillary thyroid carcinoma (PTC). Here this work focused on the mechanism of circRNA_0003892 (circ_0003892) in PTC progression. Methods. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to examine circ_0003892, microRNA-326 (miR-326) and LIM and SH3 protein 1 (LASP1) mRNA expression levels in PTC tissues and cell lines. Besides, cell counting kit-8 (CCK-8), EdU and transwell assays were conducted to detect the proliferative, migrative and invasive abilities of PTC cells, respectively. B The targeting relationships between miR-326 and circ_0003892 or LASP1 3'-UTR were verified by dual-luciferase reporter gene assay and RNA immunoprecipitation (RIP) assay. Results. Circ_0003892 expression was raised in PTC tissues and cells, which was significantly interrelated with larger tumor size and extrathyroidal extension in PTC sufferers. Overexpression of circ_0003892 significantly promoted the malignant biological behaviors of PTC cells. Additionally, miR-326 was a downstream target of circ_0003892, and miR-326 overexpression weakened the promoting effect of circ_0003892 overexpression on the malignant progression of PTC. MiR-326 specifically inhibited LASP1. Circ_0003892 positively regulated LASP1 expression by targeting miR-326. Conclusion. Circ_0003892 up-regulates LASP1 expression and facilitates PTC progression via competitively binding to miR-326.
  • Thumbnail Image
    Publication
    Restricted
    Diagnóstico de metástasis ganglionares de carcinoma papilar tiroideo midiendo tiroglobulina en la aguja de la punción. Cálculo de punto de corte optimo en nuestra serie
    (Elsevier, 2024-07-23) García-Molina, Francisco; Aguera-Sánchez, Alfonso; Peña-Ros, Emilio; Ruiz-Marín, Miguel; Martínez-Pérez, Matias; Chaves-Benito, Asunción; Martínez Díaz, Francisco; Arense Gonzalo, Julián Jesús; Oftalmología, Optometría, Otorrinolaringología y Anatomía Patológica
    La citología por punción aspiración con aguja fina (PAAF) de ganglios sospechosos cervicales de origen incierto es frecuentemente no concluyente y da falsos negativos. Para evaluar la utilidad de medir tiroglobulina en el lavado con suero fisiológico de la aguja de punción para el diagnóstico de metástasis de carcinoma papilar de tiroides, debe calcularse un punto de corte óptimo de tiroglobulina siendo positivo o negativo según los niveles de tiroglobulina fueran superiores o inferiores al punto de corte, respectivamente. Hemos estudiado retrospectivamente 33 pacientes (19 mujeres y 14 varones) de edad media de 49,3 años, con carcinoma papilar de tiroides y sospecha de metástasis ganglionar. De ellos 16 (47,1%) tuvieron una citología de la PAAF positiva. Para determinar la capacidad predictiva de tiroglobulina respecto a metástasis de carcinoma papilar de tiroides se realizó el análisis ROC que dio un área bajo la curva AUC: 0,987 (IC 95%: 0,808-1,000) obteniendo, a partir del índice de Youden, 0,4 ng/ml como punto de corte de tiroglobulina que mejor capacidad predictiva posee. El estudio de la relación entre tiroglobulina y la conservación/no conservación del tiroides mostró diferencias estadísticamente significativas (p = 0,023). Nuestros resultados validan 0,4 ng/ml de tiroglobulina como punto de corte óptimo. Al revisar la bibliografía se ve la gran diversidad de los valores de punto de corte, que se explican por la gran variabilidad interobservador e interensayo principalmente, es por ello que recomendamos calcular el punto de corte óptimo propio de cada laboratorio; y determinar en estudios posteriores dos puntos de corte según se conserve o no tiroides.
  • Thumbnail Image
    Publication
    Open Access
    Expression of Foxp3 and TLR4 in human papillary thyroid carcinoma and its clinical significance
    (Universidad de Murcia, Departamento de Biologia Celular e Histiologia, 2023) Xin, Jingwei; Fu, Haiying; Zhang, Jiaping; Zou, Hongrui; Li, Qi; Yang, Wei; Sun, Hui
    This study aimed to explore the association of Foxp3 and TLR4 with clinical pathological characteristics in papillary thyroid carcinoma (PTC) patients. Methods 78 cases of PTC were used as experimental group and 20 cases of normal thyroid tissue were used as control group. The expression of Foxp3 and TLR4 in thyroid tissue from the two groups was detected by immunohistochemistry, and the experimental group was divided into several groups on the basis of different clinicopathological indicators. The association between Foxp3 and TLR4 expression and clinicopathological parameters was statistically analyzed. Results Foxp3 and TLR4 were expressed in higher levels in PTC than in normal thyroid tissue (P<0.05). Foxp3 was mainly localized in the cytoplasm and nucleus of PTC cells, while TLR4 was found in the cytoplasm and cell membrane of cancer cells. The expression of both proteins associated with lymph node metastasis and TNM clinical stage (P<0.05). The expression of Foxp3 correlated with the expression of TLR4 in tested PTC tissues (P<0.05). In addition, the result of confocal fluorescence microscopy showed that Foxp3 and TLR4 co-localized in PTC cells. Conclusion Foxp3 and TLR4 were upregulated and associated with lymph node metastasis and advanced TNM stage in PTC tissues. Together they may act as valuable factors for the identification of high-risk PTC patients.
  • Thumbnail Image
    Publication
    Open Access
    Increased expression of CX3CL1 and CX3CR1 in papillary thyroid carcinoma
    (Universidad de Murcia, Departamento de Biologia Celular e Histiologia, 2020) Wu, Wei; Ren, Fu; Guo, Miao; Yang, Jing; Xiao, Yanjie; Liu, Wei
    CX3CL1 and its receptor CX3CR1 axis are involved in the development, progression and metastasis of many types of cancers. It has been reported that CX3CL1 and CX3CR1 expression was upregulated in some solid tumors. However, their roles in thyroid cancer remain unknown. In the present study, we investigated the expression of CX3CL1 and CX3CR1 in human papillary thyroid carcinoma (PTC) and their clinical significance. In this study, using immunohistochemistry, we examined the expression of CX3CL1 and CX3CR1 in the tissues of 26 human PTC (including 17 classical or conventional (CPTC) and 9 follicular (FVPTC) variants of PTC; 15 cases without and 11 cases with lymph node metastasis) and 10 cases of nodular goiter (NG). Compared to NG, a significant increase in the expression of CX3CL1 and CX3CR1 was found in PTC overall, as well as in CPTC and FVPTC separately. Higher CX3CL1 expression was found in CPTC than in FVPTC, but there was no significant difference in CX3CR1 expression between these subtypes of PTC. When analyzing their expressions in PTC without and with lymph node metastasis, an increased expression of CX3CL1 and CX3CR1 was observed when compared to NG respectively. There was however no significant difference in CX3CL1 and CX3CR1 expressions in PTC without lymph node metastasis when compared to PTC with lymph node metastasis. Furthermore, when compared to NG, an increased expression of CX3CL1 was correlated with an increased expression of CX3CR1 in PTC. Our data indicate that CX3CL1 and CX3CR1 can be used as tumor markers for PTC and may be potential novel targets for cancer prevention and treatment.